Nexalin explores transcranial stimulation for major depression

Nexalin Technology recently announced initiation of clinical trials, designed by researchers at the University of Pennsylvania, to assess efficacy of the company’s transcranial stimulation for major depressive disorder.

“The future of mental health is the brain — and the ability to stimulate the brain’s ability to heal itself. This clinical trial is designed so that we, Nexalin, will have no influence on the study results,” Mark White, COO of Nexalin Technology, said in a press release.

The FDA approved Nexalin transcranial stimulation (TACS) for anxiety, depression and insomnia in 2003.

The technology has been shown to decrease anxiety and depression symptoms among patients withdrawing from drug or alcohol dependence.

Nexalin TACS is currently in use at the Blake Recovery Center on Carrier Clinic Campus in New Jersey.

To assess efficacy of Nexalin TACS for major depressive disorder (MDD), researchers will conduct a 6-month trial among patients who failed to respond to medication and have been referred to electroconvulsive therapy.

“We have seen the results of the application of this treatment in our addiction center, and are honored to collaborate with Nexalin and the University of Pennsylvania on a clinical trial that shows such promise for those suffering from MDD,” Donald Parker, CEO and president of Carrier Clinic, said in the release.